Toxic epidermal necrolysis-like linear IgA bullous dermatosis after third Moderna COVID-19 vaccine in the setting of oral terbinafine

Joseph Han; Gerardo Russo; Scott Stratman; Corinna E Psomadakis; Rachel Rigo; Shayan Owji; Yen Luu; Adnan Mubasher; Belen Rubio Gonzalez; Jonathan Ungar; Joanna Harp; Cynthia Magro; Benjamin Ungar; Angela Lamb; Nicholas Gulati

doi:10.1016/j.jdcr.2022.04.021

Toxic epidermal necrolysis-like linear IgA bullous dermatosis after third Moderna COVID-19 vaccine in the setting of oral terbinafine

JAAD Case Rep. 2022 Jun:24:101-104. doi: 10.1016/j.jdcr.2022.04.021. Epub 2022 May 7.

Authors

Affiliations

¹ Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
² Department of Dermatology, University of Miami Miller School of Medicine, Miami, Florida.
³ Department of Medicine, Mount Sinai West and Morningside, New York, New York.
⁴ Department of Dermatology, Weill Cornell Medicine, New York, New York.
⁵ School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri.
⁶ Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.

No abstract available

Keywords: COVID-19 booster; COVID-19 vaccine; DILAD, drug-induced linear IgA disease; ED, emergency department; LABD, linear IgA bullous dermatosis; Moderna; TEN, toxic epidermal necrolysis; corticosteroids; drug reaction; drug-induced linear IgA disease; linear IgA bullous dermatosis; terbinafine; toxic epidermal necrolysis; toxic epidermal necrolysis-like linear IgA bullous dermatosis.

Publication types

Case Reports

Grants and funding

P30 AR079200/AR/NIAMS NIH HHS/United States